Healthcare ❯Pharmaceuticals ❯Diabetes Treatment ❯Type 2 Diabetes

CT-388 Development

Roche's Experimental Obesity Drug CT-388 Shows Significant Weight Loss in Early Trials

Patients experienced an average weight reduction of 18.8% over 24 weeks, positioning Roche as a strong contender in the competitive weight loss market.